Avelumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-metastatic Muscle Invasive Bladder Cancer

Conditions

Non-metastatic Muscle Invasive Bladder Cancer

Trial Timeline

Jun 1, 2018 → Jan 30, 2025

NCT ID

NCT03674424

About Avelumab

Avelumab is a phase 2 stage product being developed by Merck for Non-metastatic Muscle Invasive Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03674424. Target conditions include Non-metastatic Muscle Invasive Bladder Cancer.

What happened to similar drugs?

1 of 6 similar drugs in Non-metastatic Muscle Invasive Bladder Cancer were approved

Approved (1) Terminated (0) Active (5)

🔄Bicalutamide + PlaceboAstraZenecaPhase 3

🔄Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3

🔄Darolutamide (Nubeqa, BAY1841788) + PlaceboBayerPhase 3

✅Darolutamide (Nubeqa, BAY1841788)BayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03089658	Pre-clinical	Completed	—	—	Metastatic Merkel Cell Carcinoma
NCT06412848	Pre-clinical	Active	May 9, 2024	Jun 30, 2026	Urothelial Carcinoma
NCT05600127	Phase 2	Recruiting	Dec 1, 2022	Dec 1, 2026	Urothelial Carcinoma
NCT05431777	Pre-clinical	Completed	Jul 19, 2022	Jan 16, 2023	Urothelial Carcinoma
NCT05366725	Pre-clinical	Completed	Jun 29, 2022	Jun 27, 2024	Urothelial Cancer
NCT04822350	Pre-clinical	Completed	Jul 13, 2021	Apr 25, 2024	Urothelial Carcinoma
NCT03815643	Phase 3	Active	Mar 22, 2019	Feb 19, 2027	Solid Tumors
NCT03514719	Phase 1	Completed	Oct 1, 2018	Dec 2, 2021	Non Small Cell Lung Cancer
NCT03568097	Phase 2	UNKNOWN	Sep 16, 2018	Apr 1, 2024	Small Cell Lung Carcinoma
NCT03827044	Phase 3	Terminated	Aug 31, 2018	Jan 5, 2022	POLE Exonuclease Mutant Colon Cancer
NCT03674424	Phase 2	Completed	Jun 1, 2018	Jan 30, 2025	Non-metastatic Muscle Invasive Bladder Cancer
NCT03439501	Phase 2	UNKNOWN	Jan 16, 2018	Mar 30, 2022	Lymphoma, Extranodal NK-T-Cell
NCT03147404	Phase 2	Completed	Dec 28, 2017	Jul 22, 2019	Neuroendocrine Carcinoma, Grade 3
NCT03352934	Phase 2	Completed	Dec 7, 2017	Feb 18, 2022	Cancer
NCT03389126	Phase 2	Completed	Dec 1, 2017	Jan 31, 2020	Carcinoma, Hepatocellular
NCT03278379	Phase 2	Completed	Nov 15, 2017	Jul 6, 2023	Neuroendocrine Tumors
NCT03278405	Phase 1/2	Completed	Nov 15, 2017	Mar 12, 2020	Neuroendocrine Carcinoma
NCT03403777	Phase 2	Completed	Nov 15, 2017	Feb 28, 2019	Testicular Neoplasms
NCT03491345	Phase 2	UNKNOWN	Aug 1, 2017	Dec 1, 2022	PD-L1 Positive Mutation Tumor
NCT03244176	Phase 1	Active	Jul 21, 2017	Jul 1, 2025	Lymphomas Non-Hodgkin's B-Cell

Competing Products

14 competing products in Non-metastatic Muscle Invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
Bicalutamide + Placebo	AstraZeneca	Phase 3	40
Gefitinib, radiotherapy	AstraZeneca	Phase 1/2	32
Bicalutamide + Placebo	AstraZeneca	Phase 3	40
Gefitinib, 5-fluorouracil, leucovorin and radiotherapy	AstraZeneca	Phase 1/2	24
Bicalutamide + Placebo	AstraZeneca	Phase 3	40
Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigator	Novartis	Phase 3	47
HSP-130	Pfizer	Phase 2	35
AK104 + Lenvatinib	Akeso	Phase 2	39
Darolutamide (Nubeqa, BAY1841788)	Bayer	Pre-clinical	30
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide	Bayer	Pre-clinical	23
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide	Bayer	Pre-clinical	23
Darolutamide (Nubeqa, BAY1841788) + Placebo	Bayer	Phase 3	37
Darolutamide (Nubeqa, BAY1841788)	Bayer	Approved	47
Apalutamide + Darolutamide (BAY 1841788) + Enzalutamide	Bayer	Pre-clinical	23